This document provides guidance on the evaluation of new medicinal products for the treatment of attention deficit hyperactivity disorder with focus on the childhood onset.
Keywords: Attention deficit hyperactivity disorder (ADHD), children, adults, psychostimulants
Current effective version
Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)
English (EN) (158.21 KB - PDF)
Document history
Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)
English (EN) (158.21 KB - PDF)
Overview of comments received on 'Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)' (EMEA/CHMP/EWP/431734/2008)
English (EN) (401.47 KB - PDF)
Draft guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)
English (EN) (140.18 KB - PDF)
Draft concept paper on development of guideline on the treatment of attentional deficit hyperactivity disorder (ADHD)
English (EN) (36.41 KB - PDF)
Related content
- Clinical efficacy and safety: nervous system
- Directive 2001/83/EC
- Ethical considerations for clinical trials on medicinal products conducted with the paediatric population
- Adjustment for baseline covariates in clinical trials
- ICH E1 Population exposure: the extent of population exposure to assess clinical safety
- ICH E4 Dose response information to support drug registration
- ICH E9 statistical principles for clinical trials
- ICH E10 Choice of control group in clinical trials
- ICH E11(R1) step 5 guideline on clinical investigation of medicinal products in the pediatric population - Scientific guideline
- ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals - Scientific guideline
- Missing data in confirmatory clinical trials
- Need for non-clinical testing in juvenile animals on human pharmaceuticals for paediatric indications - Scientific guideline
- Pharmacokinetic studies in man